Medicine recalls
|
| |
| Batch recall of Cytosar For Inj 500mg |
| |
The Department of Health (DH) today (22 May) endorsed a licensed drug wholesaler, Pfizer Corporation Hong Kong Limited (Pfizer), to recall one batch (batch number: 3M04966 ) of Cytosar For Inj 500mg (Hong Kong Registration number: HK- 29543), from the market as a precautionary measure due to the potential quality issue.
The DH received notification from Pfizer that the overseas manufacturer of the product is initiating a voluntary recall following a complaint reporting the presence of a single glass particle following reconstitution in one single vial of one batch the product that was not supplied to Hong Kong. The concerned batch of the product were also packed from the same semi-finished product of such batch supplied in overseas. As a precautionary measure, Pfizer voluntarily recalled the affected batch from the market.
The above product, containing cytarabine, is a prescription medicine used for the treatment of several forms of leukemia. According to Pfizer, the above batch of product has been imported into Hong Kong and supplied to the Hospital Authority and local private hospital.
Pfizer has set up a hotline (2963 5514) to answer related enquiries. So far, the DH has not received any adverse reaction reports in connection with the above batch of product. The DH will closely monitor the recall.
Patients who have used the above product should consult their healthcare professionals if in doubt.
Ends/ Thursday, May 22, 2025
|
| |
